|Delivery||Report Code||Available Format|
|24-72 Working Hours||LS12112|
Diabetes mellitus is a metabolic disorder caused by high blood sugar, which, in normal cases, is regulated by the insulin hormone. In people suffering from the disease, the insulin is either not produced properly or the body fails to use it effectively, thus leading to high glucose levels in the blood. Insulin was the first medication to be discovered for diabetes, and till now, it is the safest and most-successful therapy for the disease. Over time, insulin delivery devices evolved from reusable glass syringes to pens and pumps. The home-use insulin devices market is expected to grow in the forecasted period (2020–2030) due to the favorable reimbursement scenario and strong government support in selected countries, growing diabetic population, technological advancements in such devices, and rising awareness about these devices in developing countries.
The ongoing COVID-19 pandemic has increased the demand for home-use insulin delivery devices across the globe. The reason behind this is the implementation of lockdowns and preference of people for staying at home, to reduce the chance of catching the coronavirus infection. Thus, those who used to visit clinics or hospitals for their insulin dose are now preferring to stay indoors and opting for home-use insulin delivery devices.
On the basis of product type, the home-use insulin delivery devices market is categorized into syringes, pens, pumps, and patch pumps. Among these, insulin syringes currently dominate the market, in terms of revenue, majorly due to the fact that these are easy to use at homes and the cheapest mode of delivery among all product types. Insulin patch pumps, on the other hand, are the fastest-growing category, as these products are based on advanced technologies. Additionally, they require minimum monitoring, as they automatedly monitor the blood glucose level and discharge the insulin accordingly.
On the basis of route of administration, the market is categorized into oral, transdermal, inhalation, parenteral, and other delivery routes. In 2019, parenteral delivery systems dominated the market, and they are further expected to account for the major share during the forecast period. As most subcutaneous injections provide faster effects by directly discharging the insulin into the blood, they continue to be preferred by diabetics.
Globally, North America held the largest share in the home-use insulin delivery devices market in 2019. This can be ascribed to the increasing prevalence of diabetes and promising reimbursement policies in the U.S. and Canada for diabetes treatment. For instance, the Centers for Disease Control and Prevention (CDC) reported that 34.2 million Americans were suffering from diabetes in 2019. Moreover, the increasing number of Food and Drug Administration (FDA) approvals to raise the commercial accessibility of home-use insulin delivery devices in the U.S. have led to the growth of the market in the region.
The rising prevalence of diabetes, increasing affordability of insulin delivery devices, and advancements in these systems are some of the prime factors supporting the growth of the home-use insulin delivery devices market. For instance, according to the International Diabetes Federation (IDF), in 2019, around 463 million adults aged 20–79 years were living with diabetes, and this number is expected to reach 700 million by 2045. The continuous rise in the obese population is also a major factor responsible for the growth of the market. Obesity leads to a high risk of medical conditions such as type 2 diabetes, cardiovascular problems, and hypertension. The sharp rise in the number of people with obesity across the globe is resulting in an increase in the prevalence of diabetes, thereby driving the usage of insulin infusion devices.
Key market players are actively participating in strategic activities, such as acquisitions and product launches, to gain a competitive edge in the home-use insulin delivery devices market. For instance, in 2019, Eli Lilly and Company collaborated with DexCom Inc. to produce personalized diabetes management devices. According to this agreement, Eli Lilly and Company used DexCom Inc.’s continuous glucose monitoring (CGM) devices in both the pen- and pump-based platforms.
The major players in the home-use insulin delivery devices market are Novo Nordisk A/S, Eli Lilly and Company, Tonghua Dongbao Pharmaceutical Co. Ltd., Adocia SA, Merck & Co. Inc., Sanofi SA, Biocon Ltd., Wockhardt Ltd., Gulf Pharmaceutical Industries (Julphar), Ypsomed AG, Becton, Dickinson and Company, B. Braun Melsungen AG, and Biodel Inc.
The home-use insulin delivery devices market report offers comprehensive market segmentation analysis along with market estimation for the period 2014–2030.
By Product Type
By Route of Administration